Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

For full-year 2025, Merck reported worldwide sales of $65B, up 1% Y/Y, or 2% excluding FX, while adjusted EPS totaled $8.98. Analysts had projected EPS of $8.94 for 2025 on revenue of $64.78B.

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth ...

PayPal ( PYPL) stock tumbled 16.9% before the opening bell after the fintech issued disappointing guidance, delivered weaker-than-expected Q4 earnings and revenue, and replaced its CEO. The board ...

Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance ...

The latest market snapshot at Thursday morning reveals Merck & Co shares up by 1.21%, trading at $108.19. About Merck & Co. Merck makes pharmaceutical products to treat several co ...

Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 4, Scotiabank ...

Revolution Medicines shares drop after Merck buyout talks collapse over price. Deal was valued at $28-32B before negotiations ...